NICE TAs

30/07/2025

TA1085: Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over

23/07/2025

TA1079: Fruquintinib for previously treated metastatic colorectal cancer

14/07/2025

TA752: Belimumab for treating active autoantibody-positive systemic lupus erythematosus

10/07/2025

TA1081: Zanubrutinib for treating relapsed or refractory mantle cell lymphoma

10/07/2025

TA1080: Mirikizumab for treating moderately to severely active Crohn's disease

02/07/2025

TA1076: Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)

02/07/2025

TA1077: Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over

02/07/2025

TA1075: Dapagliflozin for treating chronic kidney disease

25/06/2025

TA1078: Fosdenopterin for treating molybdenum cofactor deficiency type A

25/06/2025

TA1074: Sparsentan for treating primary IgA nephropathy

24/06/2025

TA1073: Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies

19/06/2025

TA1071: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer

19/06/2025

TA1072: Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)

18/06/2025

TA1070: Spesolimab for treating generalised pustular psoriasis flares

04/06/2025

TA1067: Linzagolix for treating symptoms of endometriosis

04/06/2025

TA1069: Efgartigimod for treating antibody-positive generalised myasthenia gravis

03/06/2025

TA1066: Somapacitan for treating growth hormone deficiency in people 3 to 17 years

28/05/2025

TA1065: Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

19/05/2025

TA596: Risankizumab for treating moderate to severe plaque psoriasis

15/05/2025

TA1063: Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment